Autres langues Tasly Pharmaceutical Group Co., Ltd

Actions

600535

CNE000001C81

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
15,36 ^CNY	+3,09 %		+0,20 %	-9,75 %

25/04	Tasly Pharmaceutical Group Co., Ltd publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/04	Tasly Pharmaceutical Group renoue avec les bénéfices en 2023 alors que le revenu d'exploitation reste stable	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat	16/04
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Shanghai Yuesai Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Tasly Pharmaceutical Group Co., Ltd, Shanghai Pudong Venture Investment Co., Ltd. and other investors	03/04
Tasly Pharmaceutical Gets Nod to Trial Stem Cell Therapy	19/01
ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units	29/12
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to S&P Global BMI Index	18/09/23
Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) added to FTSE All-World Index	18/09/23
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Mauna Kea Technologies secures an equity line financing with Vester Finance limited to a maximum of 11.4% of the capital	01/06/23
Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd	31/05/23
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23
Mauna Kea Technologies Announces Sales of EUR4.2 million for the first quarter of 2023, up 121% from 2022	21/04/23
Mauna Kea : s'envole après son chiffre d'affaires trimestriel	21/04/23
Tasly Pharmaceutical Gets Go Ahead to Launch Clinical Trial of Diabetic Kidney Drug	19/12/22
Mauna Kea Technologies reports its Financial Results for the First Half of 2022	17/11/22
Mauna Kea Technologies and Tasly Pharmaceutical Announces the Incorporation of Joint Venture in China	07/11/22
Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22
Tasly Pharmaceutical Wins Nod For Clinical Trial of Psoriasis Drug	30/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tasly Pharmaceutical Group Co., Ltd

Actions

600535

CNE000001C81

Autres langues

Filtres